Etsy Inc vs Novartis AG — how do they compare? Etsy Inc trades at $84.45 (market cap $8.14B), while Novartis AG trades at $152.4 (market cap $287.66B). The key difference: Novartis AG is far larger — about 35.3× Etsy Inc's market cap, and Novartis AG pays a 3.14% dividend while Etsy Inc pays none. Which is the better fit depends on your goals.
| ETSY | NVS | |
|---|---|---|
Market Cap | $8.14B | $287.66B |
Sector | Consumer Cyclical | Health |
52-Week High | $85.74 | $168.62 |
52-Week Low | $44.05 | $113.50 |
Enterprise Value | $9.79B | $327.68B |
Dividend Yield | — | 3.14% |
Signals from Pluang's Aura AI — not financial advice
Etsy stock trades at $83.06, up 3.14% recently and showing strong technical momentum with bullish moving average signals. The company has beaten earnings expectations for three consecutive quarters, with Q1 2026 EPS of $0.89 surpassing the $0.62 estimate. However, valuation metrics appear elevated with a P/E of 32.85 and P/B of 52.12, while the company maintains strong gross margins of 71.55% and positive operating cash flow of $693.41M in 2025.
The outlook is mixed with improving buyer momentum and AI-driven engagement tools supporting growth, but active buyer declines and high debt levels present risks. Analyst sentiment leans positive with 22 buy ratings versus 3 sells, though the consensus price target of $72.38 suggests 13% downside from current levels. The Depop divestiture to eBay removes a distraction, allowing focus on core marketplace improvements.
Novartis (NVS) trades at $150.36, down 1.96% with bearish technical signals. The company maintains strong profitability with 75.38% gross margins and 23.92% net income margin, though recent earnings show mixed results with one beat and two misses. Recent acquisitions including Myricx Bio for up to $1.5 billion expand the oncology pipeline, while regulatory approvals for Itvisma and positive drug trial data support growth prospects.
While analyst consensus leans cautious with 68% hold ratings, Novartis' robust cash flow generation and strategic pipeline investments provide long-term value. Key risks include execution challenges from recent acquisitions and competitive pressures in pharmaceuticals. The stock offers stability through strong fundamentals but faces near-term technical headwinds.
Trailing returns across standard periods
Latest headlines on both assets
Etsy operates a top-10 e-commerce marketplace operator in the U.S. and the U.K., with sizable operations in Germany, France, Australia, and Canada. The firm dominates an interesting niche, connecting buyers and sellers through its online market to exchange vintage and craft goods. With $13.5 billion in 2021 consolidated gross merchandise volume, the firm has cemented itself as one of the largest players in a quickly growing space, generating revenue from listing fees, commissions on sold items, advertising services, payment processing, and shipping labels. As of the end of 2021, the firm connected more than 96 million buyers and more than 7.5 million sellers on its marketplace properties: Etsy, Reverb (musical equipment), Elo7 (crafts in Brazil), and Depop (clothing resale).
Read more on ETSY →Novartis develops and manufactures healthcare products through two segments: Innovative Medicines and Sandoz. It generates the vast majority of its revenue from Innovative Medicines segment consisting global business franchises in oncology, ophthalmology, neuroscience, immunology, respiratory, cardio-metabolic, and established medicines. The company sells its products globally, with the United States representing close to one third of total revenue.
Read more on NVS →